Glutamate in neurologic diseases

Journal of Child Neurology

Volumn 12, Issue 8, 1997, Pages 471-485

  Bittigau, Petra ^a   Ikonomidou, Chrysanthy ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; GLUTAMIC ACID; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN ISCHEMIA; ENERGY METABOLISM; HEAD INJURY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MOTOR NEURON DISEASE; MOUSE; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SEIZURE; SPINAL CORD INJURY; SPINOCEREBELLAR DEGENERATION;

EID: 0031425189     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307389701200802     Document Type: Review

References (280)

1. Giulian D, Corpuz M, Chapman S, et al: Reactive mononuclear phagocytes release neurotoxins after ischemic nd traumatic injuries to the CNS. J Neurosci Res 1993;36:681-693.
2. Perry VH, Brown MG, Gordon S: The macrophage response to central and peripheral nerve injuries. J Exp Med 1987;165:1218-1223.
3. Coyle JT, Puttfarcken P: Oxidative stress, glutamate and neurodegenerative disorders. Science 1993;262:689-695.
4. Ikonomidou C, Turski L: Excitotoxicity and neurodegenerative diseases. Curr Opin Neurol 1995;8:487-497.
5. Meldrum BS: The role of glutamate in epilepsy and other CNS disorders. Neurology 1994;44(Suppl 2):S14-S17.
6. Beal MF: Role of excitotoxicity in human neurological disease. Curr Opin Neurol 1992;2:657-662.
7. Krebs HA: Metabolism of amino acids. III. Deamination of amino acids. Biochem J 1935;29:1620-1644.
8. Krebs HA, Eggleston LV, Hems R: Distribution of glutamine and glutamic acid in animal tissues. Biochem J 1949;44:159-163.
9. Hayashi T: A physiological study of epileptic seizures following cortical stimulation in animals and its application to human clinics. Jpn J Pharmacol 1952;3:46-64.
10. Hayashi T: Inhibition and excitation due to γ-aminobutyric acid in the central nervous system. Nature 1958;182:1076-1077.
11. Curtis DR, Phillis JW, Watkins JC: Chemical excitation of spinal neurones. Nature 1959;183:611-612.
12. Watkins JC: Thirty years of excitatory amino acid research, in Cavalheiro EA, Lehmann J, Turski L (eds): Frontiers in Excitatory Amino Acid Research. Alan R Liss, New York, 1988, pp 3-10.
13. Hollmann M, Heinemann S: Cloned glutamate receptors. Annu Rev Neurosci 1994;17:31-108.
14. McBain CJ, Mayer ML: N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 1994;74:723-760.
15. Monyer H, Seeburg PH, Wisden W: Glutamate-operated channels: Developmentally early and mature forms arise by alternative splicing. Neuron 1991;6:799-810.
16. Monyer HA, Burnashev N, Laurie DJ, et al: Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-540.
17. Nakanishi S: Molecular diversity of glutamate receptors and impucations for brain function. Science 1992;258:597-603.
18. Pin J-P, Duvoisin R: Review: Neurotransmitter receptors I. The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 1995;34:1-26.
19. Houamed KM, Kuijper JL, Gilbert TL, et al: Cloning, expression and gene structure of a G-protein-coupled glutamate receptor from rat brain. Science 1991;252:1318-1321.
20. Masu M, Tanabe Y, Tsuchida K, et al: Sequence and expression of a metabotropic glutamate receptor. Nature 1991;349:760-765.
21. Tanabe Y, Masu M, Ishii T, et al: A family of metabotropic glutamate receptors. Neuron 1992;8:169-179.
22. Tanabe Y, Nomura A, Masu M, et al: Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci 1993;13:1372-1378.
23. Akazawa C, Shigemoto R, Bessho Y, et al: Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol 1994; 347:150-160.
24. 2+ block of the N-methyl-D-aspartate receptor-mediated synaptic potentials in developing visual cortex. Proc Natl Acad Sci U S A 1993;90:7114-7118.
25. Zhong J, Gribkoff VK, Molinoff PB: Use of subunit-specific antisense oligodeoxynucleotides to define developmental changes in the properties of N-methyl-D-aspartate receptors. Mol Pharmacol 1996;50:631-638.
26. McDonald JW, Johnston MV: Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev 1990;15:41-70.
27. Pellegrini-Giampietro DE, Bennett MVL, Zukin RS: Differential expression of three glutamate receptor genes in developing rat brain: An in situ hybridization study. Proc Natl Acad Sci U S A 1991;88:4157-4161.
28. Gallo V, Upso LM, Hayes WP, et al: Molecular cloning and developmental analysis of a new glutamate receptor isoform in cerebellum. J Neurosci 1992;12:1010-1023.
29. Durand GM, Zukin RZ: Developmental regulation of mRNAs encoding rat brain kainate/AMPA receptors: A northern analysis study. J Neurochem 1993;61:2239-2246.
30. Sommer B, Köhler M, Sprengel R, Seeburg PH: RNA editing in the brain controls a determinant of ion flow in glutamate-gated channels. Cell 1991;67:11-19.
31. Bernard A, Khrestchatisky M: Assessing the extent of RNA editing in the TMII regions of GluR6 and GluR6 kainate receptors during rat brain development. J Neurochem 1994;62:2057-2060.
32. Catania MV, Landwehrmeyer GB, Testa CM, et al: Metabotropic glutamate receptors are differentially regulated during development. Neuroscience 1994;61:481-495.
33. Minakami R, Hirose E, Yoshioka K, et al: Postnatal development of mRNA specific for metabotropic glutamate receptor in the rat brain. Neurosci Res 1992;15:58-63.
34. Shigemoto R, Nakamshi S, Mizuno N: Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: An in situ hybridization study in adult and developing rat. J Comp Neurol 1992;322:121-135.
35. Bliss TVP, Collingridge GL: A synaptic model of memory: Long term potentiation in the hippocampus. Nature 1993;361:31-39.
36. Collingridge GL, Kehl SJ, McLennan H: Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J Physiol 1983;334:33-46.
37. Davis S, Butcher SP, Morris RGM: The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and long-term potentiation in vivo at intracerebral concentrations comparable to those that block LTP in vitro. J Neurosci 1992;12:21-34.
38. Morris RGM, Anderson E, Lynch GS, Baudry M: Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 1986; 319:774-776.
39. Sakimura K, Kutsuwada T, Ito I, et al: Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor ∈1 subunit. Nature 1995;373:151-155.
40. Behnisch T, Reymann KG: Co-activation of metabotropic glutamate and N-methyl-D-aspartate receptors is involved in mechanisms of long-term potentiation maintenance in rat hippocampal CA1 neurons. Neuroscience 1993;54:37-47.
41. McGuinness N, Anwyl R, Rowan M: Trans-ACPD enhances longterm potentiation in the hippocampus. Eur J Pharmacol 1991;197: 231-232.
42. Aniksztejn L, Otani S, Ben-Ari Y: Qulsqualate metabotropic receptors modulate NMDA currents and facilitate induction of long-term potentiation through protein kinase C. Eur J Neurosci 1992;4:500-505.
43. Otani S, Ben-Ari Y: Metabotropic receptor-mediated long-term potentiation in rat hippocampal slices. Eur J Pharmacol 1991; 205:325-326.
44. Musgrave MA, Ballyk BA, Goh JW: Co-activation of metabotropic and NMDA receptors is required for LTP induction. Neuroreport 1993;4:171-174.
45. Bortolotto ZA, Collingridge GL: Activation of glutamate metabotropic receptors induces long-term potentiation. Eur J Pharmacol 1992;214:297-298.
46. Bortolotto ZA, Collingridge GL: Characterization of LTP induced by the activation of glutamate metabotropic receptors in area CA1 of the hippocampus. Neuropharmacology 1993;32:1-9.
47. Zheng F, Gallagher JP: Metabotropic glutamate receptors are required for the induction of long-term potentiation. Neuron 1992;9:163-172.
48. Collins CGS: The characteristics and pharmacology of olfactory cortical LTP induced by Theta-burst high frequency stimulation and 1S,3R-ACPD. Neuropharmcology 1994;33:87-95.
49. Cline HT, Debski EA, Constantine-Paton M: N-methyl-D-aspartate receptor antagonist desegregates eye-specific stripes. Proc Natl Acad Sci U S A 1987;84:4342-4345.
50. Scherer WS, Udin SB: The role of NMDA receptors in the development of binocular maps in Xenopus tectum. Proc Soc Neurosci 1988;14:639.
51. Lincoln J, Coopersmith R, Harris EW, et al: NMDA receptor activation and early olfactory learning. Dev Brain Res 1988;39: 309-312.
52. Komuro H, Rakic P: Modulation of neuronal migration by NMDA receptors. Science 1993;260:95-97.
53. Rabacchi S, Bailly Y, Delhaye-Bouchaud N, Mariani J: Involvement of the N-methyl-D-aspartate (NMDA) receptor in synapse elimination during cerebellar development. Science 1992;256: 1823-1825.
54. Simon DK, Prusky GT, O'Leary DDM, Constantine-Paton M: TV-methyl-D-aspartate receptor antagonists disrupt the formation of a mammalian neural map. Proc Natl Acad Sci U S A 1992;89: 10593-10597.
55. Forrest D, Yuzaki M, Soares HD, et al: Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neuronal death. Neuron 1994;13:325-338.
56. Li Y, Erzurumlu RS, Chen C, et al: Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell 1994;76:427-437.
57. Trussel LO, Zhang S, Raman IM: Desensitization of AMPA receptors upon multiquantal neurotransmitter release. Neuron 1993;10:1185-1196.
58. Yamada KA, Tang CM: Benzothiadiazines inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents. J Neurosci 1993;13:3904-3915.
59. Represa A, Tremblay E, Ben-Ari Y: Kainic acid binding sites in the hippocampal mossy fibers: Localization and plasticity. Neuroscience 1987;20:739-748.
60. Debonnel G, Weiss M, De Montigny C: Reduced neuroexcitatory effect of domoic acid following mossy fiber denervation in the rat dorsal hippocampus: Further evidence that toxicity of domoic acid involves kainate receptor activation. Can J Physiol Pharmacol 1989;67:904-908.
61. Gaiarsa J-L, Zagrean L, Ben-Ari Y: Neonatal irradiation prevents the formation of hippocampal fibers and the epileptic action of kainate on rat CA3 pyramidal neurons. J Neurophysiol 1994;72:204-215.
62. Mattson MP, Lee RE, Adams ME, et al: Interactions between entorhinal axons and target hippocampal neurons: A role for glutamate in the development of hippocampal circuitry. Neuron 1988;1:865-876.
63. Weiler R, Schulte K: Ionotropic non-NMDA agonists induce retraction of dendritic spinules from retinal horizontal cells. Proc Natl Acad Sci U S A 1993;90:6533-6537.
64. Lucas DR, Newhouse JP: The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Ophthalmol 1957;58:193-201.
65. Olney JW: Brain lesions, obesity and other disturbances in mice treated with monosodium glutamate. Science 1969;164:719-721.
66. Olney JW: Glutamate-induced neuronal necrosis in the infant mouse hypothalamus: An electron microscopic study. J Neuropathol Exp Neurol 1971;30:75-90.
67. Olney JW, Sharpe LG, Feigin RD: Glutamate-induced brain damage in infant primates. J Neuropathol Exp Neurol 1972;31:464-488.
68. Olney JW, Ho OL: Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature 1970;227:609-610.
69. Olney JW: The toxic effects of glutamate and related compounds in the retina and the brain. Retina 1982;2:341-359.
70. McDonald JW, Schoepp DD: The metabotropic excitatory amino acid receptor agonist 1S,3R-ACPD selectively potentiates N-methyl-D-aspartate-induced brain injury. Eur J Pharmacol 1992;215:353-354.
71. Schoepp DD, Tizzano JP, Wright RA, Fix AS: Reversible and irreversible neuronal injury induced by intrahippocampal infusion of the mGluR agonist 1S,3R-ACPD in the rat. Neurodegeneration 1995;4:71-80.
72. Rothman SM: The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J Neurosci 1985;5:1483-1489.
73. Choi DW, Maulucci-Gedde M, Kriegstein AR: Glutamate neurotoxicity in cortical cell culture. J Neurosci 1987;7:357-368.
74. Choi DW: Ionic dependence of glutamate neurotoxicity. J Neurosci 1987;7:369-379.
75. 2+ chelators reduce early excitotoxic and ischemic neuronal injury in vitro and in vivo. Neuron 1993;11:221-235.
76. 2+ release from intracellular stores in cultured cerebral cortical neurons. J Neurochem 1991;56:1075-1078.
77. Frandsen A, Schousboe A: Mobilization of dantrolene-sensitive intracellular calcium pools is involved in the cytotoxicity induced by quisqualate and N-methyl-D-aspartate but not by 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionate and kainate in cultured cerebral cortical neurons. Proc Natl Acad Sci U S A 1992; 89:2590-2594.
78. Lee KS, Frank S, Vanderklish P, et al: Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc Natl Acad Sci U S A 1991;88:7233-7237.
79. Bartus RT, Baker KL, Heiser AD, et al: Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J Cereb Blood Flow Metab 1994;14:537-544.
80. Manev H, Favaron M, Siman R, et al: Glutamate neurotoxicity is independent of calpain I inhibition in primary cultures of cerebellar granule cells. J Neurochem 1991;57:1288-1295.
81. Rordorf G, Uemura Y, Bonventre JV: Characterization of phospholipase A2 (PLA2) activity in gerbil brain: Enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion. J Neurosci 1991;11:1829-1836.
82. Rothman SM, Yamada KA, Lancaster NL: Nordihydroguaiaretic acid attenuates NMDA neurotoxicity-action beyond the receptor. Neuropharmacology 1993;32:1279-1288.
83. Samples SD, Dubinsky JM: Aurintricarboxylic acid protects hippocampal neurons from glutamate excitotoxicity in vitro. J Neurochem 1993;61:382-385.
84. Favaron M, Manev H, Simon R, et al: Down regulation of protein kinase C protects cerebellar granule neurons in primary culture from glutamate-induced neuronal death. Proc Natl Acad Sci U S A 1990;87:1983-1987.
85. Dawson VL, Dawson TM, London ED, et al: Nitric oxide mediates glutamate neurotoxicity in primary cortical culture. Proc Natl Acad Sci U S A 1991;88:6368-6371.
86. Beckman JS, Ischiropoulos H, Zhu L, et al: Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys 1992;298:438-445.
87. Ischiropoulos H, Zhu L, Chen J, et al: Peroxynitrite-mediated tyrosine nitration catalyzed by Superoxide dismutase. Arch Biochem Biophys 1992;298:431-437.
88. Radi R, Beckman JS, Bush KM, Freeman BA: Peroxynitriteinduced membrane lipid peroxidation: The cytotoxic potential of Superoxide and nitric oxide. Arch Biochem Biophys 1991; 288:484-487.
89. Radi R, Beckman JS, Bush KM, Freeman BA: Peroxynitrite oxidation of sulfhydryls. J Biol Chem 1991;266:4244-4250.
90. Beckman JS, Ye YZ, Anderson P, et al: Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 1994;375:81-88.
91. Schulz JB, Matthews RT, Muqit MMK, et al: Inhibition of neuronal nitric oxide synthasc by 7-nitroindazole protects against MPTP induced neurotoxicity in mice. J Neurochem 1995;64:936-939.
92. Schulz JB, Matthews RT, Beat MF: Role of nitric oxide in neurodegenerative diseases. Curr Opin Neurol 1995;8:480-486.
93. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-3064.
94. Pantopoulos H, Hentze MW: Nitric oxide signaling to iron-regulatory protein: Direct control of ferritin mRNA translation and transferrin receptor mRNA stability in transfected fibroblasts. Proc Natl Acad Sci U S A 1995;92:1267-1271.
95. Clancy RM, Levartovsky D, Leszynska-Piziak J, et al: Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: Evidence for S-nitrosoglutathione as a bioactive intremediary. Proc Natl Acad Sci U S A 1994;91:3680-3684.
96. Zhang J, Dawson VL, Dawson TM, Snyder SH: Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 1994;263:687-689.
97. Brune B, Lapetina EG: Activation of a cytosolic ADP-ribosyl transferase by nitric oxide generating agents. J Biol Chem 1989;264:8455-8458.
98. Novelli A, Reilly JA, Lysko PG, Henneberry RC: Glutamate becomes neurotoxic via the W-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988;451:205-212.
99. Zeevalk GD, Nicklas WJ: Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. J Pharmacol Exp Ther 1991;257:870-878.
100. Urbanska E, Ikonomidou C, Sieklucka M, Turski WA: Aminooxyacetic acid produces excitotoxic lesions in the rat striatum. Synapse 1991;9:129-135.
101. Beal MF, Swartz KJ, Hyman BT, et al: Aminooxyacetic acid results in excitotoxic lesions by a novel indirect mechanism. J Neurochem 1991;57:1068-1073.
102. McMaster OG, Du F, French ED, Schwarcz R: Focal injection of aminooxyacetic acid produces seizures and lesions in rat hippocampus: Evidence for mediation by NMDA receptors. Exp Neurol 1991;113:378-385.
103. +) nigral toxicity in the rat by prior decortication or MK-801 treatment. Neurobiol Aging 1993; 14:295-301.
104. Beal MF, Brouillet E, Jenkins B, et al: Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192.
105. Wüllner U, Young AB, Penney JB, et al: 3-Nitropropionic acid toxicity in the striatum. J Neurochem 1994;63:1772-1781.
106. Beal MF, Brouillet E, Jenkins B, et al: Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 1993;61:1147-1150.
107. Greene JG, Porter RHP, Eller RV, et al: Inhibition of succinate dehydrogenase by malonic acid produces an excitotoxic lesion in the rat striatum. J Neurochem 1993;61:1151-1154.
108. Henshaw R, Jenkins BG, Schulz JB, et al: Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res 1994;647:161-166.
109. Schulz JB, Henshaw DR, Jenkins BG, et al: 3-Acetylpyridine produces age-dependent neuronal lesions by an excitotoxic and free radical mediated mechanism. J Cereb Blood Flow Metab 1994;14:1024-1029.
110. Ikonomidou C, Turski L: Neurodegenerative disorders: Clues from glutamate and energy metabolism. Crit Rev Neurobiol 1996;10:239-263.
111. Beal MF: Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neuron 1992;31:119-130.
112. Beal MF: Role of excitotoxicity in human neurological disease. Curr Opin Neurol 1992;2:657-662.
113. Kvamme E, Schousboe A, Hertz L, et al: Developmental change of endogenous glutamate and gamma-glutamyl transferase in cultured cerebral cortical interneurons and cerebellar granule cells, and in mouse cerebral cortex and cerebellum in vivo. Neurochem Res 1985;10:993-1008.
114. Benveniste HJ, Drejer A, Schousboe A, Diemer NH: Elevation of extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984;43:1369-1374.
115. Bouvier M, Szatkowski A, Amato A, Attwel D: The glial cell glutamate uptake carrier countertransports pH-changing anions. Nature 1992;360:471-474.
116. Meldrum BS, Garthwaite J: Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Phamiacol Sci 1990;11: 379-387.
117. Rosenberg PA, Amin S, Leitner M: Glutamate uptake disguises neurotoxic potency of glutamate agonists in cerebral cortex in dissociated cell culture. J Neurosci 1992;12:56-61.
118. Kanai Y, Hediger MA: Primary structure and functional characterization of a high affinity glutamate transporter. Nature 1992;360: 467-471.
119. +-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci U S A 1992;89: 10955-10959.
120. Rothman SM: Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci 1984;4: 1884-1891.
121. Tecoma ES, Monyer H, Goldberg MP, Choi DW: Traumatic neuronal injury in vitro is attenuated by NMDA antagonists. Neuron 1989;2:1541-1545.
122. Pulsinelli W: Pathophysiology of acute ischemic stroke. Lancet 1992;339:533-536.
123. Lipton SA: Molecular mechanisms of trauma-induced neuronal degeneration. Curr Opin Neurol 1994;6:588-596.
124. Globus MY-T, Busto R, Dietrich WD, et al: Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and γ-aminobutyric acid studied by intracerebral microdialysis. J Neurochem 1988;51:1455-1464.
125. Miyashita K, Abe H, Nakajima T, et al: Glutamate release in the gerbil hippocampus after middle cerebral artery occlusion. Neuroreport 1994;5:945-948.
126. Uchiyama-Tsuyuki Y, Araki H, Yae T, Otomo S: Changes in the extracellular concentrations of amino acids in the rat striatum during transient focal cerebral ischemia. J Neurochem 1994;62: 1074-1078.
127. 3H]-glutamate uptake into synaptosomes. J Neurochem 1986;47:1614-1619.
128. Faden AI, Demediuk P, Panter SS, Vink R: The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989;244:798-800.
129. Liu D, Thangnipon W, McAdoo DJ: Excitatory amino acids rise to toxic levels upon impact injury to the rat spinal cord. Brain Res 1991;547:344-348.
130. Palmer AM, Marion DW, Botscheller ML, et al: Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J Neurochem 1993;61:2015-2024.
131. Person L, Hillered L: Chemical monitoring of neurosurgical intensive care patients using intracerebral microdialysis. J Neurosurg 1992;76:72-80.
132. Bondoli A, Barbi S, Camaioni D, et al: Plasma and cerebrospinal fluid free amino acid concentrations in post-traumatic cerebral edema in patients with shock. Resuscitation 1981;9:119-124.
133. Baker AJ, Moulton RJ, MacMillan VH, Shedden PM: Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans. J Neurosurg 1993;79:369-372.
134. Pulsinelli W, Sarokin A, Buchan A: Antagonism of the NMDA and non-NMDA receptors in global versus focal brain ischemia. Prog Brain Res 1993;96:125-135.
135. Wahlstedt C, Golanov E, Yamamoto S, et al: Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 1993;363:260-263.
136. Buchan A: Do NMDA antagonists protect against cerebral ischemia: Are clinical trials warranted? Cerebrovasc Brain Metab Rev 1990;2:1-26.
137. Meldrum BS: Protection against ischemic neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovasc Brain Metab Rev 1990;2:27-57.
138. Simon RP, Swan JH, Griffiths T, Meldrum BS: Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984;226:850-853.
139. Lanier WL, Perkins WJ, Karlsson BR, et al: The effects of dizocilpine maleate (MK-801), an antagonist of the N-methyl-D-aspartate receptor, on ischemia in primates. J Cereb Blood Flow Metab 1990;10:252-261.
140. Diemer NH, Jorgensen MB, Johansen FF, et al: Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist NBQX. Acta Neuropathol Scand 1993;86:45-49.
141. Buchan AM, Li H, Cho S, Pulsinelli WA: Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats. Neurosci Lett 1991;132: 255-258.
142. Gill R, Nordholm L, Lodge D: The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischemia model. Brain Res 1992;580:35-43.
143. Sheardown MJ, Nielsen EO, Hansen AJ, et al: 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline: A neuroprotectant for cerebral ischemia. Science 1990;247:571-574.
144. Smith S, Meldrum BS: Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat. Stroke 1992;23:861-864.
145. Meden P, Overgaard K, Sereghy T, Boysen G: Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolie stroke model. J Neurol Sci 1993;119:209-216.
146. Overgaard K, Sereghy T, Pedersen H, Boysen G: Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke. Neurol Res 1993;15:344-349.
147. Buchan AM, Li H, Cho S, Pulsinelli WA: Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats. Neurosci Lett 1991;132:255-258.
148. Kaiser F, Hansen AJ, Laursen H, Sheardown MJ: NBQX protects against delayed cell death following complete forebrain ischemia in the rat. Mol Neuropharmacol 1992;2:219-220.
149. LePeillet E, Arvin B, Moncada C, Meldrum BS: The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischemia in the rat. Brain Res 1992;571:115-120.
150. Nellgard B, Wieloch T: Postischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia. J Cereb Blood Flow Metab 1992;12:2-11.
151. Yatsugi S, Kawasaki S, Katoh M, et al: Effects of the novel AMPA antagonist YM900 and other excitatory amino acid antagonists on the delayed neuronal death in the gerbil hippocampus. J Cereb Blood Flow Metab 1993;13(Suppl 1):S635.
152. Sheardown MJ, Suzdak PD, Nordholm L: AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischemia, even when delayed 24 h. Eur J Pharmacol 1993;236:347-353.
153. Nowicki JP, Duval H, Poignet H, Scatton B: Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. Eur J Pharmacol 1991;204:339-340.
154. G-nitro-L-arginine protects against ischemia-induced increases in nitric oxide and hippocampal neurodegeneration in the gerbii. Eur J Pharmacol 1994;260:191-200.
155. Huang Z, Huang PL, Panahian N, et al: Effects of cerebral ischemia in mice deficient of neuronal nitric oxide synthase. Science 1994;265:1883-1885.
156. Huang Z, Huang PL, Ma J, et al: Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab 1996;16:981-987.
157. Roberts-Lewis JM, Savage MJ, Marcy VR, et al: Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J Neurosci 1994;14:3934-3944.
158. Seubert P, Nakagawa Y, Ivy G, et al: Intrahippocampal colchicine injection results in spectrin proteolysis. Neuroscience 1989;31: 195-202.
159. Xue D, Slivka A, Buchan AM: Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke 1992;23:894-899.
160. Maruki Y, Köhler RC, Kirsch JR, et al: Effect of the 21-aminosteroid tirilazad on cerebral pH and somatosensory evoked potentials after incomplete ischemia. Stroke 1993;24:724-730.
161. He YY, Hsu CY, Ezrin AM, Miller MS: Polyethylene glycol-conjugated Superoxide dismutase in focal cerebral ischemia-reperfusion. Am J Physiol 1993;265:252-256.
162. Kirsch JR, Helfaer MA, Haun SE, et al: Polyethylene glycol-conjugated superoxide dismutase improves recovery of postischemic hypercapnic cerebral blood flow in piglets. Pediatr Res 1993;34: 530-537.
163. Kato C: An electrophysiological study on the effect of antioxidant drugs against retinal ischemia-reperfusion damage. Nippon Ganka Gakkai Zasshi 1995;99:552-557.
164. Faden AI, Simon EP: A potential role for excitotoxins in the pathophysiology of spinal cord injury. Ann Neurol 1988;23:623-626.
165. Faden AI, Demedjuk P, Panter SS, Vink R: The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989;244:798-800.
166. Faden AI, Salzman S: Pharmacological strategies in CNS trauma, Trends Pharmacol Sci 1992;13:29-35.
167. Inglis F; Kuroda Y, Bullock R: Glucose hypermetabolism after acute subdural hematoma is ameliorated by a competitive NMDA antagonist. J Neurotrauma 1992;9:75-84.
168. McIntosh T, Soares H, Hayes R, Simon R: The NMDA receptor antagonist MK-801 prevents edema and restores magnesium homeostasis after traumatic brain injury in rats, in Cavalheiro EA, Lehmann J, Turski L (eds): Frontiers in Excitatory Amino Acid Research. New York, Alan R Liss, 1988, pp 653-656.
169. Shapira Y, Lam AM, Eng CC, et al: Therapeutic time window and dose response of the beneficial effects of ketamine in experimental head injury. Stroke 1994;25:1637-1643.
170. Smith DH, Okiyama K, Thomas MJ, McIntosh TK: Effects of the excitatory amino acid receptor antagonist kynurenate and indole-2-carboxylic acid on behavioral and neurochemical outcome following experimental brain injury. J Neurosci 1993;13:5383-5392.
171. Toulmond S, Serrano A, Benavides J, Scatton B: Prevention by eliprodil (SL82.0715) of traumatic brain damage in the rat. Existence of a large (18h) therapeutic window. Brain Res 1993; 620:32-41.
172. Danilevich EJ, Galtseva IV, Kuznetsowa OJ, et al: The influence of ketamine anesthesia given to patients with critical trauma at the prehospital stage upon the course of outcome of shock. Vestn Khir 1990;145:104-107.
173. Belyakov VA, Sinitsyn LN, Maksimov GA, et al: Analgesia and anesthesia in patients with mechanical traumas at prehospital stage. Anesth Reanimatol 1993;5:24-32.
174. Bernert H, Turski L: Traumatic brain damage prevented by the nonN-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sul-famoylbenzo-(f)quinoxaline. Proc Natl Acad Sci U S A 1996;93: 5235-5240.
175. Wrathall JR, Teng YD, Choiniere D, Mundt DJ: Evidence that local non-NMDA receptors contribute to functional deficits in contussive spinal cord injury. Brain Res 1992;586:140-143.
176. Wrathall JR, Teng YD, Choiniere D: Amelioration of functional deficits from spinal cord trauma with systemically administered NBQX, an antagonist of non-N-methyl-D-aspartate receptors. Exp Neurol 1996;137:119-126.
177. Saatman KE, Murai H, Bartus RT, et al: Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci U S A 1996;93:3428-3433.
178. McDonald JW, Silverstein FS, Johnston MV: MK-801 protects the neonatal brain from hypoxic/ischemic damage. Eur J Pharmacol 1987;140:359-361.
179. Ikonomidou C, Price MT, Mosinger JL, et al: Hypobaric-ischemic conditions cause glutamate-like cytopathology in infant rat brain. J Neurosci 1989;9:1693-1700.
180. Ikonomidou C, Mosinger JL, Shahid Salles K, et al: Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-D-aspartate neurotoxicity. J Neurosci 1989;9:2809-2818.
181. Ikonomidou C, Qin YQ, Labruyere J, et al: Prevention of trauma-induced neurodegeneration in infant rat brain. Pediatr Res 1996; 39:1020-1027.
182. McDonald JW, Silverstein FS, Johnston MV: Neurotoxicity of JV-methyl-D-aspartate is markedly enhanced in developing rat central nervous system. Brain Res 1988;459:200-203.
183. Grafe MR: Developmental changes in the sensitivity of the neonatal rat brain to hypoxic/ischemic injury. Brain Res 1994;653: 161-166.
184. Olney JW, Ikonomidou C, Mosinger JL, Friedrich G: MK-801 prevents hypobaric-ischemic neuronal degeneration in infant rat brain. J Neurosci 1989;9:1701-1704.
185. Hagberg H, Diemer NH, Andiné P: Hypoxic-ischemic brain damage in the newborn rat: Effect of NMDA- and AMPA-receptor antagonists. Biol Neonate 1992;62:299-311.
186. Hattori H, Morin AM, Schwartz PH, Fujikawa DG, Wasterlain CG: Posthypoxic treatment with MK-801 reduces hypoxic-ischemic damage in the neonatal rat. Neurology 1989;39:713-718.
187. Albala BJ, Moshé SL, Okada R: Kainic acid-induced seizures: A developmental study. Dev Brain Res 1984;13:139-148.
188. Olney JW, Labruyere J, Wang G, et al: NMDA antagonist neurotoxicity: Mechanism of prevention. Science 1991;254:1515-1518.
189. Fix AS, Long GG, Wozniak DF, Olney JW: Pathomorphologic effects of N-methyl-D-aspartate antagonists in the rat posterior cingulate/retrosplenial cerebral cortex: A review. Drug Dev Res 1994;32:147-152.
190. Farber NB, Price MT, Labruyere J, et al: Age dependency of NMDA antagonist neurotoxicity. Soc Neurosci Abstr 1992;18:1148.
191. Meldrum BS: Excitatory amino acid transmitters in epilepsy. Epilepsia 1991;32(Suppl 2):S1-S3.
192. Meldrum BS: The role of glutamate in epilepsy and other CNS disorders. Neurology 1994;44(Suppl):S14-S23.
193. Geddes JW, Cahan LD, Cooper SM, et al: Altered distribution of excitatory amino acid receptors in temporal lobe epilepsy. Exp Neurol 1990;108:214-220.
194. McDonald JW, Garofalo EA, Hood T, et al: Altered excitatory and inhibitory amino acid receptor binding in hippocampus of patients with temporal lobe epilepsy. Ann Neurol 1991;29:529-541.
195. Represa A, Robain O, Tremblay E, Ben-Ari Y: Hippocampal plasticity in childhood epilepsy. Neurosci Lett 1989;99:351-355.
196. Sutula T, Cascino G, Cavazos J, et al: Mossy fiber synaptic reorganization in the epileptic human temporal lobe. Ann Neurol 1989;26:321-330.
197. During MJ, Spencer DD: Extracellular hippocampal glutamate and spontaneous seizures in the conscious human. Lancet 1993;341: 1605-1610.
198. Baumeister FA, Gsell W, Shin YS, Egger J: Glutamate and pyridoxine-dependent epilepsy: Neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. Pediatrics 1994;94:318-321.
199. Spink DC, Snead OC, Swann JW, Martin DL: Free amino acids in cerebrospinal fluid from patients with infantile spasms. Epilepsia 1988;29:300-306.
200. Monaco F, Gianelli M, Schiavella MP, et al: Plasma amino acid alterations in idiopathic generalized epilepsy: An investigation in probands and their first degree relatives. Ital J Neurol Sci 1994; 15:137-144.
201. Janjua NA, Itano T, Kugoh T, et al: Familial increase in plasma glutamic acid in epilepsy. Epilepsy Res 1992;11:37-44.
202. KaMainen R, Halonen T, Pitkanen A, Riekkinen PJ: Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: Effect of vigabatrin and carbamazepine monotherapies. J Neurochem 1993;60:1244-1250.
203. Croucher MJ, Collins JF, Meldrum BS: Anticonvulsant action of excitatory amino acid antagonists. Science 1992;216:899-901.
204. Meldrum BS, Croucher MJ, Badman G, Collins JF: Antiepileptic action of excitatory amino acid antagonists in the photosensitive baboon, Papio papio. Neurosci Lett 1983;39:101-104.
205. Chapman AG, Meldrum BS: Non-competitive N-methyl-D-aspartate antagonists protect against sound-induced seizures in DBA/2 mice. Eur J Pharmacol 1989;166:201-211.
206. Chapman AG, Graham JL, Patel S, Meldrum BS: Anticonvulsant activity of two orally active competitive NMDA-antagonists, CGP 37849 and CGP 39551 against sound-induced seizures in DBA/2 mice and photically induced myoclonus in Papio papio. Epilepsia 1991;32:578-587.
207. Meldrum BS: Excitatory amino acids in epilepsy and potential novel therapies. Epilepsy Res 1992;12:189-196.
208. Waldmeier PC, Baumann PA, Wicki P, et al: Similar potency of carbamazepine, oxcarbazepine and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995;45:1907-1913.
209. Subramanian S, Rho JM, Penix L, et al: Felbamate block of the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther 1995;273: 878-886.
210. Dürmüller N, Craggs M, Meldrum BS: The effect of the non-NMDA antagonists GYKI 52466 and NBQX and the competitive NMDA-receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res 1994;17:167-174.
211. Smith SE, Dürmuller N, Meldrum BS: The non-N-methyl-D-aspartate antagonists, GYKI 52466 and NBQX are anticonvulsants in two animal models of reflex epilepsy. Eur J Pharmacol 1991;201: 179-183.
212. Turski WA, Urbanska E, Dziki M, et al: Excitatory amino acid antagonists protect mice against seizures induced by bicuculline. Brain Res 1990;514:131-134.
213. Yamaguchi S, Donevan SD, Rogawski MA: Anticonvulsant activity of AMPA/kainate antagonists: Comparison of GYKI 52466 and NBQX in maximal electroshock, and chemoconvulsant seizure models. Epilepsy Res 1993;15:179-184.
214. Griffiths T, Evans MC, Meldrum BS: Temporal lobe epilepsy, excitotoxins and the mechanism of selective neuronal loss, in Fuxe K, Roberts R, Schwarcz R (eds): Excitotoxins. New York, MacMillan, 1987, pp 331-345.
215. Turski L, Cavalheiro EA, Sieklucka-Dziuba M, et al: Seizures produced by pilocarpine: Neuropathological sequelae and activity of glutamate decarboxylase in the rat forebrain. Brain Res 1986; 398:37-48.
216. Meldrum BS, Vigoroux RA, Brierley JB: Systemic factors and epileptic brain damage: Prolonged seizures in paralyzed, artificially ventilated baboons. Arch Neurol 1973;29:82-87.
217. Nevander G, Ingvar M, Auer R, Siesjö BK: Status epilepticus in well oxygenated rats causes neuronal necrosis. Ann Neurol 1985;18:281-290.
218. Olney JW, DeGubareff T, Sloviter RS: "Epileptic" brain damage in rats induced by sustained electrical stimulation of the perforant path. II. Ultrastructural analysis of acute hippocampal pathology. Brain Res Bull 1983;10:699-712.
219. Olney JW, Fuller T, Gubareff T: Acute dendrotoxic changes in the hippocampus of kainate treated rats. Brain Res 1979;176:91-100.
220. Olney JW, Collins RC, Sloviter RS: Excitotoxic mechanisms of epileptic brain damage. Adv Neural 1986;44:857-877.
221. Clifford DB, Zorumski CF, Olney JW: Ketamine and MK-801 prevent degeneration of thalamic neurons induced by focal cortical seizures. Exp Neurol 1989;105:272-279.
222. Cavalheiro EA, Silva DF, Turski WA, et al: The susceptibility of rats to pilocarpine-induced seizures is age-dependent. Dev Brain Res 1987;37:43-58.
223. Velisek L, Kubová H, Pohl M, et al: Pentylenetetrazol-induced seizures in rats: An ontogenetic study. Naunyn Schmiedebergs Arch Pharmacol 1992;346:588-591.
224. deFeo M, Mecarelli O, Ricci G: Bicuculline- and allyglycineinduced epilepsy in developing rats. Exp Neurol 1985;90:411-421.
225. Zouhar A, Marés P, Liskova-Bernaskova K, Mudrochova M: Motor and electrocorticographic epileptic activity induced by bicuculline in developing rats. Epilepsia 1989;30:501-510.
226. Marés P, Kubová H, Zouhar A, et al: Motor and electrocorticographic epileptic activity induced by 3-mercaptopropionic acid in immature rats. Epilepsy Res 1993;16:11-18.
227. Kubová H, Moshé SL: Experimental models of epilepsy in young animals. J Child Neurol 1994;9(Suppl 1):S3-S11.
228. Sperber EF, Moshé SL: Age-related differences in seizure susceptibility to fluorothyl. Dev Brain Res 1988;39:295-297.
229. Nitecka L, Tremblay E, Charton G, et al: Maturation of kainic acid seizure - brain damage syndrome in the rat. II. Histopathological sequelae. Neuroscience 1984;13:1073-1094.
230. Gilbert ME, Cain DP: A developmental study of kindling in the rat. Dev Brain Res 1982;2:321-328.
231. Moshé SL, Sharpless NS, Kaplan J: Kindling in developing rats: Afterdischarge thresholds. Brain Res 1981;211:190-195.
232. Haas K, Sperber EF, Moshé SL: Kindling in developing animals: Expression of severe seizures and enhanced development of bilateral foci. Dev Brain Res 1990;56:275-280.
233. Fujikawa DG, Soderfeldt B, Wasterlain CG: Neuropathological changes during generalized seizures in newborn monkeys. Epilepsy Res 1992;12:243-251.
234. Olney JW, Misra CH, DeGubareff T: Cysteine-S-sulfate: Brain damaging metabolite in sulfite oxidase deficiency. J Neuropathol Exp Neurol 1975;34:167-176.
235. Mudd SH, Irreverre F, Laster L: Sulfite oxidase deficiency in man: Demonstration of the enzymatic defect, Science 1967;156: 1599-1602.
236. Watkins JC: Excitatory amino acids, in McGeer E, Olney JW, McGeer P (eds): Kainic Acid as a Tool in Neurobiology. New York, Raven Press, 1978, pp 37-69.
237. Hamosh A, McDonald JW, Valle D, et al: Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant. J Pediatr 1992;121:131-135.
238. Schmitt B, Steinmann B, Gitzelmann R, et al: Nonketotic hyperglycinemia: clinical and electrophysiologic effects of dextromethorphan, an antagonist of the NMDA receptor. Neurology 1993;43:421-424.
239. Kalmanchey R, Szucs L, Majtenyi K, et al: Non-ketotic hyperglycinemia. Orv Hetil 1995;136:245-249.
240. Ohya Y, Ochi N, Mizutani N, et al: Nonketotic hyperglycinemia: Treatment with NMDA antagonist and consideration of neuropathogenesis. Pediatr Neurol 1991;7:65-68.
241. Ault B, Wang CM, Yawn BC: L-Proline depolarizes rat spinal motoneurones by an excitatory amino acid antagonist-sensitive mechanism. Br J Pharmacol 1987;92:319-326.
242. Martin D, Ault B, Nadler JV: NMDA receptor-mediated depolarizing action of proline on CA1 pyramidal cells. Eur J Pharmacol 1992;219:59-66.
243. Henzi V, Reichling DB, Helm SW, MacDermott AB: L-Proline activates glutamate and glycine receptors in cultured rat dorsal horn neurons. Mol Pharmacol 1992;41:793-801.
244. Nadler JV, Wang A, Hakim A: Toxicity of L-proline toward rat hippocampal neurons. Brain Res 1988;456:168-172.
245. Baxter CF, Baldwin RA, Davis JL, Flood JF: High proline levels in the brains of mice as related to specific learning deficits. Pharmacol Biochem, Behav 1985;22:1053-1059.
246. Ishikawa Y, Kameda K, Okabe M, et al: A case of type I hyperprolinemia associated with photogenic epilepsy. No To Hattatsu 1991;23:81-86.
247. Schwarcz R, Whetsell WO, Mangano RM: Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat striatum. Science 1983;219:316-318.
248. Do KQ, Herrling PL, Streit P, et al: In-vitro release and electrophysiological effects in situ of homocysteic acid, an endogenous N-methyl-(D)-aspartic acid agonist, in the mammalian striatum. J Neurosci 1986;6:2226-2234.
249. Gilman S, Markel DS, Koeppe RA, et al: Cerebellar and brainstem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography. Ann Neurol 1988;23:223-230.
250. Gilman S, Junck L, Markel DS, et al: Cerebral glucose hypermetabolism in Friedreich's ataxia detected with positron emission tomography. Ann Neurol 1990;28:750-757.
251. Blass JP, Shen RK-F, Cedarbaum JM: Energy metabolism in disorders of the nervous system. Rev Neurol 1988;144:543-563.
252. Hatazawa J, Brooks RA, Dalakas MC, et al: Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: A PET study. J Comput Assist Tomogr 1988;12:630-636.
253. Dalakas MC, Hatazawa J, Brooks RA, DiChiro G: Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol 1987;22:580-586.
254. Moudy AM, Handran SD, Goldberg MP, et al: Abnormal calcium homeostasis and mitochondrial polarization in a human encephalomyopathy. Proc Natl Acad Sci U S A 1995;92:729-733.
255. Brouillet E, Jenkins BG, Hyman BT, et al: Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993;60:356-359.
256. Corsini GU, Vaglini F, Fornai F, et al: (+)MK-801 prevents dopaminergic perikarya damage in MPTP and acetaldehyde-treated mice. Poster Neurosci 1991;1:33-36.
257. Greene JG, Porter RHP, Eller RV, Greenamyre JT: Inhibition of succinate dehydrogenase by malonic acid produces an excitotoxic lesion in rat striatum. J Neurochem 1993;61:1151-1154.
258. Lange KW, Löschmann P-A, Sofic E, et al: The competitive NMDA antagonist CPP protects substantia nigra from MPTP-induced degeneration in primates. Naunyn Schmiedebergs Arch Pharmacol 1993;348:569-575.
259. Lange KW, Youdim MBH, Riederer P: Neurotoxicity and neuroprotection in Parkinson's disease. J Neural Transm Suppl 1992; S38:27-44.
260. Mihatsch W, Russ H, Przuntek H: Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: Effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine. J Neural Transm 1988;71:177-188.
261. + neurotoxicity by N-methyl-D-aspartate antagonist. Brain Res 1992;586:203-207.
262. +) nigral toxicity in the rat by prior decortication or MK-801 treatment: A stereological estimate of neuronal loss. Neurobiol Aging 1993;14:295-301.
263. Storey E, Hyman BT, Jenkins B, et al: 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 1992;58: 1975-1978.
264. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349:414-418.
265. Zuddas A, Oberto G, Vaglini F, et al: MK-801 prevents MPTP-induced parkinsonism in primates. J Neurochem 1992;59:733-739.
266. Turski L, Ikonomidou C: Glutamate, energy metabolism and neuropathology: Relevance to neurodegenerative disorders, in Martignoni E, Nappi G (eds): Parkinson's Disease and Extrapyramidal Disorders. London, Smith-Gordon, 1994, pp 15-22.
267. Ludolph AC, Seelig MO, Ludolph A, et al: ATP deficits and neuronal degeneration induced by 3-nitropropionic acid. Ann N Y Acad Sci 1992;648:300-302.
268. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994;36:882-888.
269. Schulz JB, Matthews RT, Henshaw DR, Beal MF: Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases. Neuroscience 1996;71:1043-1048.
270. Knecht KT, Mason RP: In vivo spin trapping of xenobiotic free radical metabolites. Arch Biochem Biophys 1993;303:185-194.
271. Schulz JB, Henshaw DR, Siwek D, et al: Involvement of free radicals in excitotoxicity in vivo. J Neurochem 1995;64:2239-2247.
272. Way LW, Trevor AJ: Pharmacology of intravenous nonnarcotic anesthetic, in Miller RD (ed): Anesthesia. Churchill Livingstone, 1986, pp 799-800.
273. Olney JW, Labruyere J, Wang G, et al: NMDA antagonist neurotoxicity: Mechanism of prevention. Science 1991;254: 1515-1518.
274. Fix AS, Long GG, Wozniak DF, Olney JW: Pathomorphologic effects of N-methyl-D-aspartate antagonists in the rat posterior cingulate/retrosplenial cerebral cortex: A review. Drug Dev Res 1994;32:147-152.
275. Campociaro P, Coyle JT: Ontogenetic development of kainate neurotoxidty: Correlates with glutamatergic innervation. Proc Natl Acad Sci U S A 1978;75:2025-2029.
276. Ikonomidou C, Labruyere J, Benz A, Olney JW: Antagonistic pharmacology of glutamate toxicity in infant rat brain. Soc Neurosci Abstr 1989;15:767.
277. Ben-Ari Y, Tremblay E, Berger M, Nitecka L: Kainic acid seizure syndrome and binding sites in developing rats. Dev Brain Res 1984;14:284-288.
278. Takemoto T: Isolation and structural identification of naturally occurring excitatory amino acids, in McGeer E, Olney JW, McGeer P (eds): Kainic Acid as a Tool in Neurobiology. New York, Raven Press, 1978, pp 1-17.
279. Pearl TM, Bedard L, Kosatsky T, et al: An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 1990;322:1775-1780.
280. Teitelbaum JS, Zatorre RJ, Carpenter S, et al: Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 1990;322:1781-1787.